SWA
UNCY icon

SOA Wealth Advisors’s Unicycive Therapeutics UNCY Stock Holding History

SOA Wealth Advisors’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-100
Closed -$794 – 912
2024
Q4 		$794 Buy
+100
New +$554 ﹤0.01% 747

Other funds holding UNCY

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SOA Wealth Advisors's UNCY Position: Q1 2025 in Review

SOA Wealth Advisors sold out of Unicycive Therapeutics (UNCY) in Q1 2025, closing a stake of 100 shares — an estimated $794 sold.

SOA Wealth Advisors first reported a position in UNCY in Q4 2024 and held it in 1 quarter. The position peaked at $794 in Q4 2024. 29 funds tracked by Wall St. Rank hold UNCY as of Q1 2025.

  • SOA Wealth Advisors reported no remaining Unicycive Therapeutics position as of Q1 2025 after selling out during the quarter.
  • SOA Wealth Advisors sold 100 Unicycive Therapeutics shares in Q1 2025, an estimated $794.
  • SOA Wealth Advisors first reported a position in Unicycive Therapeutics in Q4 2024 and held it in 1 quarter.
  • SOA Wealth Advisors's Unicycive Therapeutics position peaked at $794 in Q4 2024.
  • 29 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q1 2025.

Based on SOA Wealth Advisors's 13F filing for Q1 2025, filed 14 Apr 2025.